Drospirenone litigation: Does the punishment Fit the crime?

Pelin Batur, Petra Marcela Casey

Research output: Contribution to journalReview article

Abstract

There has been much controversy in the scientific literature and lay press about the potential for increased relative risks (RRs) of venous thromboembolism associated with certain contraceptives over others. This commentary reviews the conflicting data on drospirenone's relative venous and arterial risks and summarizes the details of over two billion dollars in litigation surrounding the use of these products. The current legal environment supports litigation focused on small potential RRs, associated with even smaller absolute risks. The absolute risks of venous and arterial thrombotic events in drospirenone users are low and comparable to that of other combined hormonal contraceptives. Women should have access to a wide array of contraceptive choices, including those containing drospirenone.

Original languageEnglish (US)
Pages (from-to)99-102
Number of pages4
JournalJournal of Women's Health
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Punishment
Jurisprudence
Crime
Contraceptive Agents
Literature
Venous Thromboembolism
drospirenone

Keywords

  • drospirenone
  • litigation
  • oral contraceptive
  • venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Drospirenone litigation : Does the punishment Fit the crime? / Batur, Pelin; Casey, Petra Marcela.

In: Journal of Women's Health, Vol. 26, No. 2, 01.02.2017, p. 99-102.

Research output: Contribution to journalReview article

@article{69af0e2566d543649177eaa0b612898e,
title = "Drospirenone litigation: Does the punishment Fit the crime?",
abstract = "There has been much controversy in the scientific literature and lay press about the potential for increased relative risks (RRs) of venous thromboembolism associated with certain contraceptives over others. This commentary reviews the conflicting data on drospirenone's relative venous and arterial risks and summarizes the details of over two billion dollars in litigation surrounding the use of these products. The current legal environment supports litigation focused on small potential RRs, associated with even smaller absolute risks. The absolute risks of venous and arterial thrombotic events in drospirenone users are low and comparable to that of other combined hormonal contraceptives. Women should have access to a wide array of contraceptive choices, including those containing drospirenone.",
keywords = "drospirenone, litigation, oral contraceptive, venous thromboembolism",
author = "Pelin Batur and Casey, {Petra Marcela}",
year = "2017",
month = "2",
day = "1",
doi = "10.1089/jwh.2016.6092",
language = "English (US)",
volume = "26",
pages = "99--102",
journal = "Journal of women's health (2002)",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Drospirenone litigation

T2 - Does the punishment Fit the crime?

AU - Batur, Pelin

AU - Casey, Petra Marcela

PY - 2017/2/1

Y1 - 2017/2/1

N2 - There has been much controversy in the scientific literature and lay press about the potential for increased relative risks (RRs) of venous thromboembolism associated with certain contraceptives over others. This commentary reviews the conflicting data on drospirenone's relative venous and arterial risks and summarizes the details of over two billion dollars in litigation surrounding the use of these products. The current legal environment supports litigation focused on small potential RRs, associated with even smaller absolute risks. The absolute risks of venous and arterial thrombotic events in drospirenone users are low and comparable to that of other combined hormonal contraceptives. Women should have access to a wide array of contraceptive choices, including those containing drospirenone.

AB - There has been much controversy in the scientific literature and lay press about the potential for increased relative risks (RRs) of venous thromboembolism associated with certain contraceptives over others. This commentary reviews the conflicting data on drospirenone's relative venous and arterial risks and summarizes the details of over two billion dollars in litigation surrounding the use of these products. The current legal environment supports litigation focused on small potential RRs, associated with even smaller absolute risks. The absolute risks of venous and arterial thrombotic events in drospirenone users are low and comparable to that of other combined hormonal contraceptives. Women should have access to a wide array of contraceptive choices, including those containing drospirenone.

KW - drospirenone

KW - litigation

KW - oral contraceptive

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85012079675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012079675&partnerID=8YFLogxK

U2 - 10.1089/jwh.2016.6092

DO - 10.1089/jwh.2016.6092

M3 - Review article

C2 - 27854556

AN - SCOPUS:85012079675

VL - 26

SP - 99

EP - 102

JO - Journal of women's health (2002)

JF - Journal of women's health (2002)

SN - 1540-9996

IS - 2

ER -